Index that tracks impact of pharmaceuticals worldwide to relaunch, focus on more diseases
The Global Health Impact Index, developed by faculty at Binghamton University, State University of New York to rank pharmaceutical companies based on their drugs’ impact on global health, is launching a new, more-robust model that addresses even more diseases worldwide.
A re-launch event, “The Global Health Impact Project: Progress Towards the Sustainable Development Goals,” will takes place from noon-5 p.m. Friday, May 10, in 002 Robertston Hall at the Liechtenstein Institute of Self-Determination at Princeton University. A new website and models will be introduced, and two roundtable discussions will follow.
The Global Health Impact Index was first launched at the World Health Organization in Geneva in 2015 by Binghamton University Associate Professor of Philosophy Nicole Hassoun.
“Measuring the impact and effectiveness of essential treatments is crucial for a variety of stakeholders to determine where to allocate healthcare resources, and what medications should be prioritized in initiatives meant to advance global health,” said Hassoun. “We must ask ourselves, what medications offer the greatest relief for malaria, for tuberculosis, for HIV/AIDS, and what pharmaceutical companies have been making a socially-responsible effort to alleviate the global burden of disease?”
The new index confronts these uncertainties, and is a first step toward momentous change, said Hassoun. The new index also considers drugs’ impacts over time, across countries and diseases, and assesses different parts of the pharmaceutical supply chain—showing how generics companies contribute to getting drugs to the people who need them.
“A lot of attention has been paid in determining the need for different drugs, but the Global Health Impact Index actually addresses the impact that these drugs are having globally,” said Hassoun. “Having this information readily available could help improve the overall delivery of drugs and help save millions of lives.”
The index looks at three things: the need for several important drugs for tuberculosis, HIV/AIDS, malaria and multiple neglected tropical diseases; the drugs’ effectiveness; and the number of people who can access these drugs. Each company’s score is the sum of its drugs’ impacts.
Previously, the Global Health Impact Index utilized a preliminary model to evaluate the impact of medications used to treat HIV/AIDS, malaria, and tuberculosis. The Global Health Impact project has greatly expanded its scope to include a multitude of other diseases plaguing both developing and developed countries. The new models include a variety of neglected tropical diseases (NTDs) that primarily impact low-impact communities around the world. While previous indexes have only measured the need for different drugs worldwide, the Global Health Impact Index is the first to measure the impact of these drugs.